Altogether, data presented in this study demonstrate that expression of TAA as an actA-fusion from recombinant Lm induces significant anti-tumor immunity as a preventative melanoma vaccine, and that immunity can be enhanced by treatment with CPB therapy after vaccination. This evidence concerns the gene ACTA1 and neoplasm.